Arylamide compounds and compositions and uses thereof

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

2. A composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

3. The composition of claim 2 which is in the form of a powder.

4. The composition of claim 2 further comprising an additional medicament.

5. The composition of claim 4 wherein the additional medicament is chosen from an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent, and an anti-hypertensive agent.

6. The composition of claim 5 wherein the antibiotic is chosen from an aminoglycoside, a cephalosporin, a diaminopyridine, a fluoroquinolone, a sulfonamide, and a tetracycline.

7. The composition of claim 5 wherein the antibiotic is chosen from amikacin, azithromycin, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, chloramphenicol, ciprofloxacin, clindamycin, colistin, domeclocycline, doxycycline, erythromycin, gentamicin, mafenide, methacycline, minocycline, neomycin, norfloxacin, ofloxacin, oxytetracycline, polymyxin B, pyrimethamine, silver sulfadiazine, sulfacetamide, sulfisoxazole, tetracycline, tobramycin, and trimethoprim.

8. The composition of claim 5 wherein the anti-inflammatory agent is a steroidal agent or a non-steroidal agent.

9. The composition of claim 8 wherein the steroidal agent is chosen from dexamethasone, rimexolone, prednisolone, fluorometholone, and hydrocortisone, and wherein the non-steroidal agent is chosen from a cyclooxygenase type I or type II inhibitor, a PAF antagonist, a PDE IV inhibitor, and an inhibitor of cytokine production.

10. The composition of claim 9 wherein the cyclooxygenase type I or type II inhibitor is chosen from diclofenac, flurbiprofen, ketorolac, suprofen, nepafenac, amfenac, indomethacin, naproxen, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, mefanamic acid, diflusinal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, tenoxicam, carprofen, vioxx, celecoxib, and etodolac.

11. The composition of claim 9 wherein the PAF antagonist is chosen from apafant, bepafant, minopafant, nupafant, and modipafant.

12. The composition of claim 9 wherein the PDE IV inhibitor is chosen from ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, and roflumilast.

13. The composition of claim 5 wherein the anti-allergic agent is pemirolast or olopatadine.

14. The composition of claim 5 wherein the anti-allergic agent is a corticosteroid.

15. The composition of claim 14 wherein the corticosteroid is chosen from prednisolone, fluorometholone, loteprenol, and dexamethasone.

16. A method of treating a bacterial infection of the eye in a mammal comprising administering to the mammal in need thereof an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, or a composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

17. A composition comprising a compound having the formula:

or a pharmaceutically acceptable salt thereof, and an aminoglycoside, a cephalosporin, or a fluoroquinolone.

18. The composition of claim 17 wherein the aminoglycoside is gentamicin, the cephalosporin is ceftazidime or ceftriaxone, and the fluoroquinolone is ciprofloxacin.

19. The composition of claim 2 further comprising a cyclodextrin.

20. The method of claim 16 wherein the bacterial infection is chosen from Pseudomonas aeruginosa, Klebsiella pneumonia, Enterococcus faecalis, Eschericia coli, Staphylococcus aureus, Streptococcus viridans , and Streptococcus pneumonia.

21. The composition of claim 2 , wherein the pharmaceutically acceptable salt thereof is in the form of a hydrochloride acid addition salt.